Glenmark Pharma on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.
Topics
Glenmark Pharmaceuticals | Allergies | USFDA
Glenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.
The company's fully-owned unit Glenmark Specialty SA (Switzerland) has received approval from the USFDA for its new drug application (NDA) for Ryaltris, a fixed-dose (metered), prescription, combination nasal spray, Glenmark Pharmaceuticals said in a statement.
The product is used for the treatment of symptoms of seasonal allergic rhinitis in adults and pediatric patients 12 years of age and older, it added.
The FDA's approval of Ryaltris represents a major milestone for Glenmark and clearly supports our efforts to bring innovative treatment options in our key therapeutic areas," said Robert Crockart, Chief Commercial Officer of Glenmark Pharmaceuticals Limited.
With this NDA approval, the company looks forward to bringing this new medicine to physicians and their patients for the treatment of symptoms of seasonal allergic rhinitis, including nasal and ocular symptoms, he added.
Ryaltris will be marketed and distributed in the United States by Hikma Specialty USA, Inc, as part of its exclusive licensing agreement with Glenmark Specialty SA.
Ryaltris has been approved and is marketed in Australia, the Czech Republic, Poland, Russia, South Africa, Ukraine, the United Kingdom, and Uzbekistan.
In April 2021, Glenmark concluded the regulatory procedure in Europe, enabling approval in 17 countries across the EU and UK.
The drug firm has entered into commercial agreements with several partners around the world, including Menarini for the commercialisation of the drug in select EU markets and with Bausch Health in Canada.
The product is under review by Health Canada). (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
English (US)